Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

CRP-albumin-lymphocyte (CALLY) Index Is an Independent Prognostic Factor for the Esophageal Cancer Patients Who Received Curative Treatment

TORU AOYAMA, ITARU HASHIMOTO, YUKIO MAEZAWA, KENTARO HARA, KEISUKE KAZAMA, KEISUKE KOMORI, MASAKATSU NUMATA, AYAKO TAMAGAWA, MOMOKO FUKUDA, HARUHIKO CHO, JUNYA MORITA, SUZUE YOSHIZAWA, KAZUKI OTANI, AYA KATO, MIE TANABE, MASATO NAKAZONO, SHINNOSUKE KAWAHARA, TAKASHI OSHIMA, AYA SAITO, NORIO YUKAWA and YASUSHI RINO
Anticancer Research February 2024, 44 (2) 815-822; DOI: https://doi.org/10.21873/anticanres.16873
TORU AOYAMA
1Department of Surgery, Yokohama City University, Yokohama, Japan;
2Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: t-aoyama{at}lilac.plala.or.jp
ITARU HASHIMOTO
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKIO MAEZAWA
1Department of Surgery, Yokohama City University, Yokohama, Japan;
2Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ykzawa0{at}gmail.com
KENTARO HARA
1Department of Surgery, Yokohama City University, Yokohama, Japan;
3Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEISUKE KAZAMA
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEISUKE KOMORI
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAKATSU NUMATA
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AYAKO TAMAGAWA
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MOMOKO FUKUDA
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HARUHIKO CHO
1Department of Surgery, Yokohama City University, Yokohama, Japan;
3Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUNYA MORITA
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUZUE YOSHIZAWA
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUKI OTANI
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AYA KATO
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MIE TANABE
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASATO NAKAZONO
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINNOSUKE KAWAHARA
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI OSHIMA
1Department of Surgery, Yokohama City University, Yokohama, Japan;
2Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AYA SAITO
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIO YUKAWA
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUSHI RINO
1Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Corrigenda - August 01, 2024

Abstract

Background/Aim: Perioperative inflammation and the nutritional status affect both short- and long-term oncological outcomes in various malignancies. We clarified the clinical impacts of the CRP-albumin-lymphocyte (CALLY) index in patients with esophageal cancer who received curative treatment. Patients and Methods: The present study included 180 patients who underwent curative treatment for esophageal cancer between 2005 and 2020. The prognosis and clinicopathological parameters were compared between a high-fibrinogen group and a low-fibrinogen group. Results: The 3- and 5-year overall survival rates were 50.0% and 42.6%, respectively, in the CALLY index-low group, and 75.9% and 66.6% in the CALLY index-high group. The differences between the two groups were statistically significant (p<0.001). Univariate and multivariate analyses demonstrated that the CALLY index was an independent prognostic factor [hazard ratio=2.310, 95% confidence interval=1.416-3.767, p<0.001]. Similar results were observed in recurrence-free survival. When comparing the details of postoperative surgical complications, there was a significant difference in the incidence of anastomotic leakage. The incidence of anastomotic leakage was 40.2% in the CALLY index-low group, while it was 27.5% in the CALLY index-high group (p=0.030). Conclusion: The pretreatment CALLY index is one of the independent prognostic factors for esophageal cancer. The CALLY index might become a promising biomarker for the treatment and management of esophageal cancer.

Key Words:
  • CRP-albumin-lymphocyte index
  • CALLY
  • esophageal cancer
  • curative treatment
  • prognostic factor
  • biomarker
  • Received December 6, 2023.
  • Revision received December 27, 2023.
  • Accepted December 28, 2023.
  • Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 44 (2)
Anticancer Research
Vol. 44, Issue 2
February 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
CRP-albumin-lymphocyte (CALLY) Index Is an Independent Prognostic Factor for the Esophageal Cancer Patients Who Received Curative Treatment
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
CRP-albumin-lymphocyte (CALLY) Index Is an Independent Prognostic Factor for the Esophageal Cancer Patients Who Received Curative Treatment
TORU AOYAMA, ITARU HASHIMOTO, YUKIO MAEZAWA, KENTARO HARA, KEISUKE KAZAMA, KEISUKE KOMORI, MASAKATSU NUMATA, AYAKO TAMAGAWA, MOMOKO FUKUDA, HARUHIKO CHO, JUNYA MORITA, SUZUE YOSHIZAWA, KAZUKI OTANI, AYA KATO, MIE TANABE, MASATO NAKAZONO, SHINNOSUKE KAWAHARA, TAKASHI OSHIMA, AYA SAITO, NORIO YUKAWA, YASUSHI RINO
Anticancer Research Feb 2024, 44 (2) 815-822; DOI: 10.21873/anticanres.16873

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
CRP-albumin-lymphocyte (CALLY) Index Is an Independent Prognostic Factor for the Esophageal Cancer Patients Who Received Curative Treatment
TORU AOYAMA, ITARU HASHIMOTO, YUKIO MAEZAWA, KENTARO HARA, KEISUKE KAZAMA, KEISUKE KOMORI, MASAKATSU NUMATA, AYAKO TAMAGAWA, MOMOKO FUKUDA, HARUHIKO CHO, JUNYA MORITA, SUZUE YOSHIZAWA, KAZUKI OTANI, AYA KATO, MIE TANABE, MASATO NAKAZONO, SHINNOSUKE KAWAHARA, TAKASHI OSHIMA, AYA SAITO, NORIO YUKAWA, YASUSHI RINO
Anticancer Research Feb 2024, 44 (2) 815-822; DOI: 10.21873/anticanres.16873
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Clinical Relevance of the CALLY Index in Prognostic Stratification of Intrahepatic Cholangiocarcinoma
  • The Hemoglobin, Albumin, Lymphocyte and Platelet (HALP) Score as an Independent Prognostic Factor for Esophageal Cancer Patients who Received Curative Treatment
  • The Clinical Impact of the Prognostic Immune and Nutritional Index in Gastric Cancer Patients Who Received Curative Treatment
  • The Prognostic Immune and Nutritional Indices Are Independent Prognostic Factors for Esophageal Cancer Patients Who Receive Curative Treatment
  • Google Scholar

More in this TOC Section

  • Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort
  • Unfavorable Outcomes of T3N0 Remnant Gastric Cancer After Distal Gastrectomy
  • Circulating Tumor DNA Methylation Level Is a More Accurate Prognostic Biomarker in Colon Cancer
Show more Clinical Studies

Keywords

  • CRP-albumin-lymphocyte Index
  • CALLY
  • Esophageal cancer
  • curative treatment
  • prognostic factor
  • biomarker
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire